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Abstract 
Solid phase extraction coupled with liquid chromatography tandem mass spectrometry 
provides a robust and sensitive approach for the identification and quantitation of 
specialized pro-resolving mediators (lipoxins, resolvins, protectins and maresins), their 
pathway markers and the classic eicosanoids. Here, we provide a detailed description of 
the methodologies employed for the extraction of these mediators from biological systems, 
setup of the instrumentation, sample processing and then the procedures followed for their 
identification and quantitation. 
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1. Introduction 
The role of lipid mediators in regulating distinct aspects of the body’s functions in humans 
and experimental systems is well appreciated [1-4]. In this chapter, we shall detail the 
methodologies pioneered in the Serhan laboratory to obtain a snapshot of the dynamic 
pathways for the four major bioactive metabolomes that include the arachidonic acid 
eicosapentaenoic acid and docosahexaenoic acid metabolomes [5-12]. These 
methodologies provide insights into mechanisms activated during inflammation as well as 
new leads into underlying causes of disease by measuring the flux down each of the major 
bioactive metabolomes [5-11]. The methodologies that will be discussed herein employ 
C18 based extraction to enrich for lipid mediators in biological systems. These are then 
coupled with reverse phase liquid chromatography electrospray tandem mass 
spectrometry that allows for the separation, identification and quantitation of these 
molecules [6,10]. Given that the structures of these mediators are conserved throughout 
evolution, these methodologies are applicable to biological material from experimental 
systems such as tunicates [13], mice [5,7] and baboons [9] as well as humans 
[6,8,14,15,11]. Thus, they facilitate the direct translation of findings made in experimental 
systems to humans and vice versa.  
 
2. Materials 
All solvents should be LC/MS or analytical grade. All stocks should be handled 
using zero dead volume Hamilton syringes. Ensure that the Hamilton syringes are 
appropriately cleaned using isopropanol and methanol; this should be done by 
aliquoting at least 20 syringe volumes with each solvent. Please note that these 
compounds are sensitive to light, oxygen and heat. They should be stored at -20 
°C or -80 °C, and exposure to light should be minimized. Each time the stock is 
used, purge the vial with a gentle stream of nitrogen very briefly before closing it to 
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prevent oxidative degradation. DO NOT use these compounds with DMSO because 
the SPM are sensitive to isomerization and oxidation in this solvent. 
 
2.1 Sample preparation and Solid Phase Extraction 
1. Methanol (MeOH) is used for protein precipitation and sample extraction as well 
as solid phase extraction (SPE) cartridge equilibration 
2.  For washing of SPE cartridges use n-hexane  
3.  Methyl formate is used as SPE elution solvent 
4. Isolute 500 mg / 3mL C18 SPE columns are used(Biotage) 
5  Deuterium-labelled internal standards used for quantification can be found inTable 
1. 
 
 
 
1.  
2.  
2.2 Liquid chromatography tandem mass spectrometry 
1. Water containing 0.01 % acetic acid is used as solvent A 
2. MeOH containing 0.01 % acetic acid is used as solvent B 
3. LC-MS standards (see Table 2-4)  
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4. A Poroshell 120 EC-18 4.6 mm ×100 mm × 2.7 µm reversed phase column is 
employed (Agilent) 
3. Methods 
3.1 Preparing standard mixes for internal standards and standard curves 
3.1.2 Determining the concentration of synthetic material 
1. Blank the UV spectrophotometer using the solvent of interest. 
2. Aliquot a known volume of the stock using a Hamilton syringe 
3. Measure the UV absorbance ensuring that a characteristic chromophore is 
observed for the molecule of interest (i.e. diene, triene or tetraene) [6] 
4. Calculate absorption using a 3 point dropline 
            5. Calculate concentration using Beer-Lambert law: 
Concentration = absorbance/extinction coefficient*dilution (See Table 5 for 
lmaxMEOH and extinction co-efficients for each conjugated double bond system) 
 
3.2 Tuning of the LC-MS-MS for Lipid mediator profiling 
 
1. Using synthetic standards, first tune the probe position to maximize signal  
2. Next, adjust electrode position 
3. Afterwards, in the instrument parameters window adjust curtain gas, collisionally 
activated dissociation (CAD) gas, electrode voltage, source temperature and the 
source gases one at a time to identify optimal source settings. 
4. Subsequently tune the compound parameters (Declustering Potential, Entrance 
Potential, Collision Energy, and Collision Cell Exit Potential) for each compound 
and for each transition  
5. It is suggested that for each compound (both pathway markers & mediators) at 
least 2 transitions are used 
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3.3 Automated Lipid Mediator extraction 
3.3.1 Sample preparation 
1. Ensure that samples have not been freeze-thawed, fresh samples are preferred 
2. For frozen samples allow to defrost on ice 
3. For tissues dissociate gently in ice-cold MeOH ensuring that the samples remain 
cold throughout the process. 
4. For liquid samples (e.g. cell culture preparations and plasma) add 4 equal 
volumes of ice-cold methanol containing deuterium-labelled internal standards to 
each sample 
5. Place at -20 °C for 45 min to allow for protein precipitation 
6. Centrifuge samples at 2000 ×g for 10 min at 4 °C  
7. Collect supernatant 
8. Transfer tubes to TurboVap Evaporator 
 
9.  Ensure that the water bath is set to 37 °C 
 
10. Turn nitrogen feed on and set the flow rate to no more than 15 psi 
 
11. Ensure that the lid is closed 
 
12. Methanol volume should be evaporated to less than 1 mL using a steady nitrogen 
stream 
 
13. Centrifuge samples at 2000 × g for 10 min at 4oC 
 
14. Samples are now ready for extraction. At this stage samples should not be stored 
 
3.3.2 Lipid Mediator Extraction 
1. Add new C18 columns on the rack 
2. Add the collection plates containing elution tubes 
3. Make sure run through plate is at position D  
4. Click “run single method” 
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5. Select the extraction method 
6. Click “prepare run” 
7. Go to solvent feeder (5) and prime each individually (make sure, the containers 
are filled, especially the MF) 
8. Go to extraction media (3) and select how many columns you will use 
9. Go to solvent tips (1) and sample tips (2) and check tips are filled as displayed on 
screen. If necessary, add or delete missing columns (or add tips)  
10. Click “run method” 
11. Monitor that the extraction procedure initiated correctly 
12. At the end of the extraction, transfer the eluted samples (i.e. the MF fraction) to 
glass tubes, rinse the collection tube or the collecting well once with MeOH and 
add to the sample  
13. Samples are ready for drying on Turbovap  
 
3.3.3 Solvent Evaporation 
1. Switch the TurboVap Evaporator on 
2. Ensure that the water bath is set to 37 °C 
 
3. Turn nitrogen feed on and set the flow rate to no more than 15 psi 
 
4. Place 10mL conical borosilicate tubes containing the methylformate fraction or 
methanol fraction obtained during solid phase extraction in the TurboVap 
 
5. Ensure that the lid is closed 
 
6. When the solvent is more than 95% evaporated rinse the walls of the tube using 
methylformate 
 
7. When the solvent is more than 95% evaporated rinse the walls of the tube using 
methanol 
 
8. When the solvent is completely evaporated, add 40µl of methanol/water (1:1) 
 
9. Centrifuge the tube at 2000 × g for 2 min 
 
10. Carefully transfer the supernatant to an injection vial insert 
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11. Place the insert in a clearly labelled 1.5 mL eppendorf tube 
 
12. Centrifuge the insert at 10000 × g for no more than 2 min 
 
13. Transfer the supernatant to an injection vial insert and place the insert in a clearly 
labelled sample vial. 
 
14. Samples are now ready for LC-MS-MS profiling. 
 
 
3.4 Chromatography 
 
1. Using an Poroshell 120 EC-18 (4.6 mm × 100 mm × 2.7 µm) and water containing 
0.01% acetic acid as solvent A, and methanol containing 0.01% acetic acid as 
solvent B, the following gradient should be used to chromatographically separate 
the mediators from their isomers and pathway markers 
2. Column temperature should be set at 50 °C 
3. Equilibrate the column with mobile phase at 80:20 (A:B)  
4. This should be ramped to 50:50 (A:B) over 12 seconds 
5. The gradient should be maintained for 2 minutes 
6. Then to 80:20 over the subsequent 9 min 
7. This should be maintained for the next 3.5 min  
8. Then ramped to 98:2 (A:B)  
9. Finally maintain this for 5.4 min to wash the column 
10. The follow rate should be maintained at 0.5 mL/min throughout the experiment 
 
3.5 Data analysis using Analyst Quantitate tool 
 
3.5.1 Setting up a quantitation method 
 
1. In Analyst Click on Build Quantitation Method 
2. Select a file that contains a standard mix 
3. Assign which transitions correspond to the internal standards  
9 
 
4. Assign the internal standards that will be used for identification and quantitation of 
each molecule. 
5. In the Integrate tab select a retention time window of not more than 5 seconds 
6. Save the method 
 
3.5.2 Analysing the data 
1. Click the quantitation wizard and follow the instructions to load your samples and 
the appropriate analysis method obtained as detailed above 
2. Start by integrating the deuterium-labelled internal standards making a note of any 
drifts from the expected retention times 
3. If retention-time drifts are observed correct the expected retention times for each 
of the analyte according to the retention time drift observed in the respective 
internal standards being used for identification (e.g. if d5-LXA4 is observed to elute 
2 seconds after the anticipated retention time then LXA4 expected retention time 
will also shift by 2 seconds) 
4. After determining the expected retention times for each of the samples integrate 
each of the mediators. Here all peaks that are clearly visible even if not more than 
3 times higher than baseline should be integrated. 
5. After integrating all the peaks in explore mode search for MS-MS spectra for 
molecules where a peak was obtained in at least 1 transition in the same region of 
the chromatogram where the peak was recorded.  
6. Compare the tandem mass spectrum obtained in the sample with that obtained 
from the synthetic/authentic compound matching at least 6 ions in the MS-MS 
spectrum, with one of the ions being derived from a backbone break. These can 
be compared and matched to the Spectra Book available for all of these mediators 
and pathways on the Serhan lab website. 
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7. For those molecules where the MS-MS spectrum is a positive match proceed to 
quantitation using a standard curve constructed using either synthetic or authentic 
standard mixes with concentrations determined as detailed above. 
8. For molecules where standards are not available, molecules that carry similar 
physical properties may be used. 
9.  If an MS-MS spectrum is not obtained for a molecule or group of molecules and 
additional sample is available this could be re-run looking specifically for the 
molecule(s) where a spectrum was not obtained.  
10. If no additional sample is available then the identification criteria are not fulfilled. 
 
4. Notes 
1.  Concentrated HCl and acetic acid should be handled in a fumehood. Gloves and 
eye protection need to be wore at all times when handling these acids. Also 
always add the acid to water to avoid injury..  
2. All standard stocks should be stored under nitrogen, shielded from light and at -
20oC for short-term storage and -80oC for long-term storage. 
3. Each time the stock is used, purge the vial with a gentle stream of nitrogen very 
briefly before closing it to prevent oxidative degradation.  
4.  All solvents are flammable, they should be handled with care in a fumehood and 
kept away from open flames 
5.  All compound stocks should be handled using zero dead volume Hamilton 
syringes 
6 Ensure that the Hamilton syringes are appropriately cleaned using isopropanol 
and methanol; this should be done by aliquoting at least 20 syringe volumes with 
each solvent. 
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7.  Only use nitrogen or an inert gas to evaporate solvents, do not use air since this 
will lead to mediator oxidation. 
8 Upon solvent evaporation and suspension of samples in water/methanol samples 
need to be profiled within 24h to avoid isomerization of the mediators. At all times 
samples should be kept at 4oC and not frozen to maximise mediator integrity. 
9. DO NOT DMSO at any stage since SPM are sensitive to isomerization and 
oxidation in this solvent. 
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Table 1 List of deuterated internal standards, their complete stereochemistries and 
source. 
  
Abbreviation Trivial name Full stereochemistry Source 
5S-HETE-d8 
Deuterium-labelled 
5S-HETE 
5S-hydroxy-eicosa-6E,8Z,11Z,14Z-tetraenoic-5,6,8,9,11,12,14,15-
d8 acid 
Cayman Chemicals 
LTB4-d4 
Deuterium-labelled 
leukotriene B4 
5S,12R-dihydroxy-eicosa-6Z,8E,10E,14Z-tetraenoic-6,7,14,15-
d4 acid 
Cayman Chemicals 
LXA4-d5 
Deuterium-labelled 
lipoxin A4 
5S,6R,15S-trihydroxy-eicosa-7E,9E,11Z,13E-tetraenoic-
19,19,20,20,20-d5 acid 
Cayman Chemicals 
RvD2-d5 
Deuterium-labelled 
resolvin D2 
7S,16R,17S-trihydroxy-docosa-4Z,8E,10Z,12E,14E,19Z-hexaenoic-
21,21,22,22,22-d5 acid 
Cayman Chemicals 
PGE2-d4 
Deuterium-labelled 
prostaglandin E2 9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid 
Cayman Chemicals 
 
 
 
Table 2 List of arachidonic acid metabolome, their complete stereochemistries and 
source. 
Abbreviation Trivial name Full stereochemistry Source 
AA Arachidonic acid eicosa-5Z,8Z,11Z,14Z-tetraenoic acid Cayman Chemicals 
PGD2 Prostaglandin D2 9α,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid Cayman Chemicals 
PGE2 Prostaglandin E2 9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid Cayman Chemicals 
PGF2a Prostaglandin F2a 9α,11α,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid Cayman Chemicals 
TxB2 Thromboxane B2 9α,11,15S-trihydroxy-thromba-5Z,13E-dien-1-oic acid Cayman Chemicals 
LTB4 Leukotriene B4 5S,12R-dihydroxy-eicosa-6Z,8E,10E,14Z-tetraenoic acid Cayman Chemicals 
LXA4 Lipoxin A4 5S,6R,15S-trihydroxy-eicosa-7E,9E,11Z,13E-tetraenoic acid Cayman Chemicals 
LXB4 Lipoxin B4 5S,14R,15S-trihydroxy-eicosa-6E,8Z,10E,12E-tetraenoic acid Cayman Chemicals 
15-HETE  15S-hydroxy-eicosa-5Z,8Z,11Z,13E-tetraenoic acid Cayman Chemicals 
12-HETE  12-hydroxy-eicosa-5Z,8Z,10E,14Z-tetraenoic acid Cayman Chemicals 
5-HETE  5S-hydroxy-eicosa-6E,8Z,11Z,14Z-tetraenoic acid Cayman Chemicals 
Δ6-trans-LTB4 Δ6-trans-leukotriene B4 
5S,12R-dihydroxy-eicosa-6E,8E,10E,14Z-tetraenoic acid Cayman Chemicals 
5S,12S-diHETE  5S,12S-dihydroxy-eicosa-6E,8E,10E,14Z-tetraenoic acid Biogenic synthesis 
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Table 3 List of eicosapentaenoic acid metabolome, their complete stereochemistries and 
source. 
Abbreviation Trivial name Full stereochemistry  
EPA  eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic acid Cayman Chemicals 
RvE1 Resolvin E1 5S,12R,18R-trihydroxy-eicosa-6Z,8E,10E,14Z,16E-pentaenoic acid 
Cayman Chemicals 
RvE2 Resolvin E2 5S,18R-dihydroxy-eicosa-6Z,8E,11E,14E,16Z-pentaenoic acid Biogenic synthesis 
RvE3 Resolvin E3 17R,18R/S-dihydroxy-eicosa-5Z,8Z,11Z,13E,15E-pentaenoic acid 
Custom Synthesis (Dr 
Makoto Arita, Riken 
Institute Japan) 
18-HEPE  18-hydroxy-eicosa-5Z,8Z,11Z,14Z,16E-pentaenoic acid Cayman Chemicals 
15-HEPE  15-hydroxy-eicosa-5Z,8Z,11Z,13E,17Z-pentaenoic acid Cayman Chemicals 
12-HEPE  12-hydroxy-eicosa-5Z,8Z,10E,14Z,17Z-pentaenoic acid Cayman Chemicals 
5-HEPE  5-hydroxy-eicosa-6E,8Z,11Z,14Z,17Z-pentaenoic acid Cayman Chemicals 
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Table 4 List of docosahexaenoic acid metabolome, their complete stereochemistries and 
source. 
Abbreviation Trivial name Full stereochemistry  
DHA  docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic acid Cayman Chemicals 
RvD1 Resolvin D1 7S,8R,17S-trihydroxy-docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid 
Cayman Chemicals 
RvD2 Resolvin D2 7S,16R,17S-trihydroxy-docosa-4Z,8E,10Z,12E,14E,19Z-hexaenoic acid 
Cayman Chemicals 
RvD3 Resolvin D3 4S,7R,17S-trihydroxy-docosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid 
Cayman Chemicals 
RvD4 Resolvin D4 4S,5R,17S-trihydroxy-docosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic 
acid 
Custom Synthesis (Dr 
Charles Serhan 
RvD5 Resolvin D5 7S,17S-dihydroxy-docosa-4Z,8E,10Z,13Z,15E,19Z-hexaenoic acid Cayman Chemicals 
RvD6 Resolvin D6 4S,17S-dihydroxy-docosa-5E,7Z,10Z,13Z,15E,19Z-hexaenoic acid Biogenic Synthesis 
MaR1 Maresin 1 7R,14S-dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid Cayman Chemicals 
4S,14S-diHDHA  4S,14S-dihydroxy-docosa-5Z,7E,10E,12Z,16E,19E-hexaenoic acid Biogenic Synthesis 
7S,14S-diHDHA  7S,14S-dihydroxy-docosa-4Z,8E,10E,12Z,16E,19E-hexaenoic acid Biogenic Synthesis 
PD1 Protectin D1 10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid Custom Synthesis (Dr Charles Serhan) 
10S,17S-diHDHA Protectin Dx 10S,17S-dihydroxy-docosa-4Z,7Z,11E,13Z,15E,19Z-hexaenoic acid Cayman Chemicals 
22-OH-PD1 22-OH-Protectin D1 
10R,17S,20-trihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic 
acid 
Custom Synthesis (Dr 
Trond V. Hansen, 
University of Oslo) 
17-HDHA  17-hydroxy-docosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid Cayman Chemicals 
14-HDHA  14S-hydroxy-docosa-4Z,7Z,10Z,12E,16Z,19Z-hexaenoic acid Cayman Chemicals 
13-HDHA  13-hydroxy-docosa-4Z,7Z,10Z,14E,16Z,19Z-hexaenoic acid Cayman Chemicals 
7-HDHA  7-hydroxy-docosa-4Z,8E,10Z,13Z,16Z,19Z-hexaenoic acid Cayman Chemicals 
4-HDHA  4-hydroxy-docosa-5E,7Z,10Z,13Z,16Z,19Z-hexaenoic acid Cayman Chemicals 
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Table 4 List of aspirin triggered mediators, their complete stereochemistries and source. 
Abbreviation Trivial name Full stereochemistry  
AT-LXA4 Aspirin-triggered lipoxin A4 
5S,6R,15R-trihydroxy-eicosa-7E,9E,11Z,13E-tetraenoic acid Cayman Chemicals 
AT-LXB4 Aspirin-triggered lipoxin B4 
5S,14R,15R-trihydroxy-eicosa-6E,8Z,10E,12E-tetraenoic acid Cayman Chemicals 
AT-RvD1 Aspirin-triggered Resolvin D1 7S,8R,17R-trihydroxy-docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid 
Cayman Chemicals 
AT-RvD3 Aspirin-triggered Resolvin D3 
4S,7R,17R-trihydroxy-docosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic 
acid 
Custom Synthesis (Dr 
Charles Serhan) 
AT-PD1 Aspirin-triggered Protectin D1 
10R,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic 
acid 
Custom Synthesis (Dr 
Charles Serhan) 
 
 
Table 5 Extinction co-efficient and lmaxMEOH for distinct conjugated double bond systems 
Double bond system Extinction Co-efficient lmaxMEOH 
Conjugated diene 
(e.g:monohydroxy acids) 
25,000 235 
Two conjugated dienes (e.g. 
RvD5) 
25,000 240 
Diene-triene conjugated 
system (e.g. RvE1) 
40,000 271 
Conjugated Triene (e.g. PD1) 40,000 269 
Conjugated Tetraene (e.g. 
RvD1) 
50,000 301 
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Figure Legends 
 
Figure 1. Sample preparation. Tissues from various origins (human or animal tissues or 
fluids, mice, planaria, cell culture, etc.) should be homogenized in ice-cold MeOH 
containing deuterated internal standards. Samples should always be kept on ice to 
prevent mediator isomerization. For biological fluids 4 volumes of methanol should be 
added to the samples. Homogenized tissues and biological fluids should then be kept at -
20°C for 45 min to allow for protein precipitation. Samples should then be centrifuged, 
supernatant collected and acidified to pH 3.5 with HCl prior to solid phase extraction. The 
eluting fraction containing the bioactive lipid mediators is dried under a gentle flux of 
nitrogen (N2) and resuspended in phase prior injection. MeOH, methanol; H2O, water; 
MF, methyl formate; N2, nitrogen.  
 
Figure 2. Schematic of instrument setup for mediator identification. Samples in 
phase are injected using a HPLC-MS-MS system, no more than 40µl should be injected. 
LC, liquid chromatography; RP, reverse phase; MeOH, methanol; ESI, electron spay 
ionization; m/z, mass to charge ratio; MRM, multiple reaction monitoring; EPI, enhanced 
product ion 
 
Figure 3. Lipid mediator identification and quantification. Identification of bioactive 
LM is performed by matching retention time (RT) and at least 6 diagnostic ions from the 
MS-MS spectrum with those of synthetic or authentic standards for each mediator. 
Quantitation is achieved using linear regression curves that are constructed using 
synthetic or authentic standards for each mediator of interest. Interrelationship(s) for 
identified mediators within each condition and between different conditions is further 
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investigated using multivariate analysis. LM, lipid mediator; RT, retention time; AUC, area 
under the curve; PCA, principal component analysis; PLS-DA, partial least square-
discriminant analysis; OPLS-DA, orthogonal partial least square-discriminant analysis  
 
 
